ION expands ETF trading capabilities with Tradeweb integration
DUBLIN - Goldman Sachs & Co. LLC reported its trading activity in Avadel Pharmaceuticals PLC (NASDAQ:AVDL) shares, disclosing positions representing approximately 1.17% long interest and 0.71% short interest in the company's ordinary shares as of November 18.
According to a regulatory filing submitted Wednesday under Irish Takeover Panel rules, Goldman Sachs held 1,045,379 relevant securities long and 629,728 short, along with derivatives positions of 99,632 long and 63,843 short.
The filing detailed numerous transactions conducted on November 18, including multiple purchases of Avadel shares at prices ranging from $23.05 to $23.12 per share. The transactions also included various loan returns, new loans, and borrow transactions.
Goldman Sachs is serving as an advisor to Avadel Pharmaceuticals, as noted in the disclosure. The firm is classified as an exempt principal trader without recognized intermediary status, or with recognized intermediary status but not dealing in a client-serving capacity.
The disclosure was made in compliance with Rule 38.5(b) of the Irish Takeover Panel Act, which requires certain disclosures from connected exempt principal traders during takeover situations.
Avadel Pharmaceuticals is an Ireland-based biopharmaceutical company. The filing did not provide details about any ongoing takeover activity involving the company.
The information was disclosed through a Form 38.5(b) filing with the Irish Takeover Panel, as required under Irish securities regulations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.